NCT00350636

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 789 (actual)
• Sponsor: Watson Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Oxybutynin topical gel	1 application daily to skin for 12 weeks
OTHER	Placebo topical gel	1 application daily to skin for 12 weeks

Timeline

• Start date: 2006-06-01
• Primary completion: 2007-05-01
• Completion: 2007-05-01
• First posted: 2006-07-11
• Last updated: 2010-05-10
• Results posted: 2010-05-10

Locations

63 sites across 1 country: United States